Danaher Corporation Earnings Recaps
Q2 2026
Jul 23, 2026
Shares fell 10.9% following the quarter as investors reacted negatively to cautious commentary around demand headwinds in developed markets, shipment timing disruptions, and continued margin pressure despite stable revenue growth.
Key takeaways
- Reported sales of $6.3 billion with 3% core revenue growth year-over-year; core ex-respiratory testing up 4.5%, accelerating from Q1.
- Developed markets showed slight core revenue decline due to shipment timing issues in biotechnology and weaker respiratory revenue.
- High-growth markets expanded over 10%, including mid-single-digit growth in China driven by Cytiva partnerships.
- Life sciences and diagnostics segments remained stable but not enough to offset concerns about margin compression and commercial execution challenges in certain regions.
- Management maintained a cautiously optimistic outlook but signaled ongoing uncertainty around Biotechnology shipment timing and macroeconomic factors impacting developed regions.
Q1 2026
Apr 21, 2026
Danaher delivered a solid start to 2026 with modest core revenue growth driven by strength in bioprocessing and Life Sciences, amid a lighter respiratory season; adjusted EPS rose nearly 10%, supported by operational efficiencies and strategic M&A activity.
Key takeaways
- Core revenue increased 0.5% YoY, with a 3% growth in non-respiratory segments offsetting a 2.5% decline in respiratory revenue.
- Adjusted EPS grew 9.5% to $2.06, aided by cost savings and robust free cash flow generation of $1.1 billion.
- Strategic M&A progress includes the pending Masimo acquisition, expected to be accretive within the first year and deliver high single-digit Returns by Year 5.
- Growth in China accelerated, with Life Sciences and Biotechnology outperforming expectations despite continued headwinds in Diagnostics.
- Operational focus remains on leveraging DBS to enhance innovation, margins, and customer value, with new product launches reinforcing competitive positioning.